Severe Toxicosis Secondary to Accidental Oclacitinib Ingestion in Three Cats Authors: Jessica Kielb Basile, Sara C. Lister Published: 2026 ABSTRACT ABSTRACTObjectiveTo describe the clinical course, outcome, necropsy findings, possible mechanisms of toxicosis, and treatment implications for three cats with acute kidney injury and associated systemic signs secondary to accidental oclacitinib ingestion.Series SummaryThree cats ingested large (>100 mg/kg) overdoses of oclacitinib, leading to severe acute kidney injury and associated systemic illness. Two of the three cats subsequently died or were euthanized, while the third cat made a full recovery after receiving intensive supportive care. Necropsies were performed on the two deceased cats, with no definitive mechanism for toxicosis identified.New or Unique Information ProvidedThis is the first case series of accidental oclacitinib toxicosis in cats. Recognition of this emerging concern can aid clinicians in minimizing exposure risks where possible, as well as providing prompt treatment in overdose situations. Abbreviations Animal Poison Control Center acute kidney injury alanine transaminase cardiovascular gastrointestinal Janus kinase lactated Ringer's solution reference interval total plasma protein concentration Introduction Oclacitinib1 is a veterinary‐use‐only Janus kinase (JAK) inhibitor approved for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs [1]. In dogs and cats at recommended doses, oclacitinib has rare and mild adverse effects [2, 3]. In human medicine, JAK inhibitors are used as an immunomodulatory class of medications to treat a variety of inflammatory and immunologic conditions. Various adverse events with this drug class have been reported in people, including increased risk for thromboembolism, cancer, infection, and death [4, 5]. In September 2021, the US Food and Drug Administration issued a black box warning for JAK inhibitors in people due to the associated adverse effects. Reports involving overdose, toxicosis, or acute kidney injury (AKI) could not be found in human literature. Oclacitinib was the first JAK inhibitor approved for veterinary use in dogs in June 2013 and has been used for a variety of conditions, including several off‐label uses in cats [6, 7, 8, 9, 10]. Since the introduction of the chewable formulation with increased palatability, there has been a notable increase in the number of reported overdoses and the total dosage ingested [11]. As a result, previously undescribed toxicosis involving multiple body systems is emerging that has resulted in significant illness and death in both cats and dogs. Affected systems include gastrointestinal (GI), cardiovascular (CV), hematologic, CNS, renal, hepatic, and ocular. Currently, there are two reports of oclacitinib toxicosis in dogs and cats, as well as one report of oclacitinib toxicosis causing AKI in a dog [12, 13, 14]. The mechanism of toxicosis remains unknown. This case series describes the clinical course and outcome in multiple feline overdoses and aims to increase awareness of this emerging toxicosis. Case Series Case 1 A 6.5‐year‐old neutered female domestic shorthair weighing 4.79 kg presented for acute vomiting, anorexia, and periocular edema approximately 12 h after ingesting thirty 16‐mg oclacitinib1 chewable tablets (100 mg/kg). This cat was previously healthy with no recent blood work performed. A veterinary poison control hotline2 was contacted at the time of exposure, and the owner believed a canine housemate had ingested the medication. The risk was assessed as low for the dog and most likely to cause mild GI upset and lethargy. The dog remained asymptomatic, but approximately 12 h later, the cat developed acute vomiting (containing an unquantifiable amount of chewable oclacitinib material), anorexia, and periocular edema. On presentation to a veterinarian, physical examination and vital signs were normal. Due to fractious behavior, isoflurane3 and oxygen were administered to facilitate IV catheter placement and blood collection. Serum biochemistry4 showed hyperglycemia (blood glucose concentration [BG] 12.2 mmol/L, reference interval [RI]: 4–8.7 mmol/L) (221 mg/dL, RI: 74–159 mg/dL), azotemia (BUN 14.6 mmol/L, RI: 5.7–12.9 mmol/L [41 mg/dL, RI: 16–36 mg/dL], creatinine [crea] 583 µmol/L, RI: 71–212 µmol/L [6.6 mg/dL, RI: 0.8–2.4 mg/dL]), hypophosphatemia (phos) (0.94 mmol/L, RI: 1–2.4 mmol/L) (2.9 mg/dL, RI: 3.1–7.5 mg/dL), hypokalemia (K) (3.1 mmol/L, RI: 3.5–5.8 mmol/L) (3.1 mEq/L, RI: 3.5–5.8 mEq/L), and high alanine transaminase (ALT) (171 U/L, RI: 12–130 U/L). A CBC was unremarkable. Treatment was instituted with 48 h of continuous IV lactated Ringer's solution (LRS)5 (100 mL/kg/day) and enrofloxacin6 (1 mL, concentration unknown, IM, q 24 h for two doses). Approximately 60 h after ingestion, recheck serum biochemistry showed progressive azotemia (BUN 33.9 mmol/L [95 mg/dL], crea too high to read) and static ALT (167 U/L). The cat was discharged at that time. Within 1 h of discharge, the cat vomited and began displaying abnormal behavior (howling, walking low to the ground, appearing sedate) and was immediately taken to a 24‐h facility for further evaluation. On presentation, the cat was hypothermic at 36.2°C (97.1°F), 5% dehydrated, vocalizing, and painful on kidney palpation. Blood work7 revealed a metabolic acidosis (pH 7.19, RI: 7.25–7.43, bicarbonate 14.3 mmol/L, RI: 15–27 mmol/L) with severe azotemia (BUN 59.6 mmol/L [167 mg/dL], crea 1618 µmol/L [18.3 mg/dL]), low ionized calcium (iCa) (0.61 mmol/L, RI: 1.21–1.51 mmol/L) (2.4 mg/dL, RI: 4.8–6 mg/dL), and hyponatremia (144 mmol/L, RI: 148–163 mmol/L) (144 mEq/L, RI: 148–163 mEq/L). Urine specific gravity was 1.022, and urinalysis showed glucosuria, trace ketones, proteinuria, and bacteriuria with occasional white blood cells. Abdominal ultrasound demonstrated bilateral renomegaly with mildly hyperechoic and thickened cortices consistent with acute renal insult. The cat was hospitalized and administered LRS5 (60 mL/kg/day), maropitant8 (1 mg/kg, IV, q 24 h), pantoprazole9 (1 mg/kg, IV, q 12 h), ondansetron10 (0.2 mg/kg, IV, q 8 h), and buprenorphine11 (0.015 mg/kg, IV, q 8 h). The cat did not produce any urine overnight; therefore, an indwelling urinary catheter12 was placed for monitoring. Anuria persisted despite administration of furosemide13 (2 mg/kg, IV). At 72 h following ingestion, blood work7 showed persistent metabolic acidosis (pH 7.19) with progressive azotemia (BUN too high to read, crea 1706 µmol/L [19.3 mg/dL]) and new hyperkalemia (8.1 mmol/L [8.1 mEq/L]). The cat also developed respiratory distress with open‐mouth breathing. Due to anuric AKI and hyperkalemia, hemodialysis was recommended; this was declined, with humane euthanasia chosen instead. Necropsy14 revealed mild, multifocal, acute tubular degeneration and necrosis with multifocal granular casts and intratubular mineralization. The urinary bladder had mild multifocal acute hemorrhage with superficial ectatic vessels. The pancreas had moderate chronic interstitial fibrosis with multifocal fat necrosis, focal aneurysm, and mild multifocal islet amyloidosis. Within the jejunum and duodenum, there was mild chronic lymphoplasmacytic enteritis with mucosal fibrosis. Complete mineral screens on fresh samples of liver and kidney showed normal levels of arsenic, cadmium, calcium, cobalt, copper, iron, lead, magnesium, manganese, molybdenum, selenium, thallium, and zinc. The final diagnosis reported was mild acute renal tubular necrosis. Case 2 A 7‐year‐old neutered male domestic shorthair weighing 4.96 kg presented to an emergency hospital approximately 12 h after ingesting forty 16‐mg chewable oclacitinib tablets (129 mg/kg). The cat was tachycardic (288/min) on presentation. A veterinary poison control hotline2 was contacted, and the risk was assessed as medium with potential for GI upset, stimulatory signs, ocular changes, AKI, and liver injury; hospitalization with IV fluid therapy and monitoring was recommended. Baseline blood work4 showed normal BUN (8.6 mmol/L, RI: 5.7–12.9 mmol/L) (24 mg/dL, RI: 16–36 mg/dL), crea (168 µmol/L, RI: 70–212 µmol/L) (1.9 mg/dL, RI: 0.8–2.4 mg/dL), PCV (0.37 L/L, RI: 0.3–0.45 L/L) (37%, RI: 30%–45%), and total plasma protein concentration (TP) (8 g/dL, RI: 6.0–8 g/dL). Mild hypokalemia (3.3 mmol/L, RI: 3.5–5.8 mmol/L) (3.3 mEq/L, RI: 3.5–5.8 mEq/L) and hypophosphatemia (0.97 mmol/L, RI: 1–2.4 mmol/L) (3 mg/dL, RI: 3.1–7.5 mg/dL) were present. The cat was given one oral dose of activated charcoal with sorbitol15 (0.5 g/kg) and hospitalized on 0.45% sodium chloride16 (60 mL/kg/day, IV), maropitant7 (1 mg/kg, IV, q 24 h), and ondansetron10 (0.3 mg/kg, IV, q 8 h). Approximately 24 h after ingestion, the cat developed mild periocular swelling and elevated nictitans. Recheck blood work showed mild anemia (PCV 0.23 L/L [23%], TS 6 g/dL), azotemia (BUN 13.9 mmol/L [39 mg/dL], crea 398 µmol/L [4.5 g/dL]), and hypocalcemia (iCa 1.85 mmol/L, RI: 1.95–2.8 mmol/L) (7.4 mg/dL, RI: 7.8–11.3 mg/dL). The cat's urinary bladder was moderate in size and easily expressed. Due to the development of azotemia, the IV fluid rate was increased to 120 mL/kg/day. At approximately 40 h after ingestion, blood work showed static anemia (PCV 0.22 L/L [22%], TP 5.8 g/dL), progressive azotemia (BUN 24 mmol/L [67 mg/dL], crea 690 µmol/L [7.8 mg/dL]), and hyperkalemia (5.9 mmol/L [5.9 mEq/L]). The cat appeared painful on abdominal palpation with a small urinary bladder. Methadone17 (0.2 mg/kg, IV) and propofol18 (3 mg/kg, IV) were administered to facilitate placement of an indwelling urinary catheter12. Urine production remained absent over the next 8 h despite furosemide13 (2 mg/kg, IV bolus followed by a 0.5 mg/kg/h constant rate infusion). A transfer for hemodialysis was recommended; however, cardiopulmonary arrest occurred 48 h after ingestion before transfer occurred, and the cat died. Necropsy19 showed acute tubular necrosis within the renal cortex, medulla, and loop of Henle. There was dilation of the tubular lumen and granular and cellular casts. Few lymphocytes and plasma cells were present within the interstitium, and hyalinization of the tubular basement membranes was observed. The renal changes were consistent with acute tubular injury secondary to ischemia or nephrotoxin. The cat was also diagnosed with pulmonary edema, brain edema, parathyroid chief cell hypertrophy, and mild multifocal hepatocyte vacuolation. The pathology report noted that pulmonary edema could have been a direct consequence of toxicity, secondary to fluid overload, or postmortem artifact. There were no respiratory changes noted prior to the patient's death to suggest the presence of pulmonary edema secondary to fluid overload. Case 3 A 3‐year‐old neutered female domestic shorthair weighing 3.76 kg was referred to a specialty hospital after ingesting thirty‐one 16‐mg chewable oclacitinib tablets (131.9 mg/kg). The exposure had occurred the previous night, with several piles of vomitus containing chewed material found the next morning. Approximately 8 h after ingestion, the cat was evaluated by the primary care veterinarian. A baseline CBC4 showed hematocrit 42% (RI: 29%–48%), leukopenia (3.1 × 109/L, RI: 3.6–16 × 109/L) (3.1 × 103/µL, RI: 3.5–16 × 103/µL), neutropenia (1.984 × 109/L, RI: 2.5–8.5 × 109/L) (1.984 × 103/µL, RI: 2.5–8.5 × 103/µL), and lymphopenia (0.868 × 109/L, RI: 1.2–8.0 × 109/L) (0.868 × 103/µL, RI: 1.2–8.0 × 103/µL). Chemistry panel4 showed an elevated ALT (342 U/L, RI: 10–100 U/L), aspartate aminotransferase (162 U/L, RI: 0–100 U/L), crea (248 µmol/L, RI: 53–212 µmol/L) (2.8 mg/dL, RI: 0.6–2.4 mg/dL), and BG (15.3 mmol/L, RI: 3.5–9.4 mmol/L) (278 mg/dL, RI: 64–170 mg/dL). There was mild hypophosphatemia (0.68 mmol/L, RI: 0.8–2.7 mmol/L) (2.1 mg/dL, RI: 2.4–8.4 mg/dL) and hypokalemia (3.2 mmol/L, RI: 3.4–5.6 mmol/L) (3.2 mEq/L, RI: 3.4–5.6 mEq/L). Urinalysis20 showed a urine specific gravity of 1.021, a pH of 6, 3+ proteinuria, 3+ glucosuria, and fine granular casts. Urine protein:creatinine ratio4 was 7.9 (RI: <0.5). The cat was given a total of 300 mL subcutaneous LRS5 over the day. Approximately 16 h after ingestion, recheck serum biochemistry panel4 showed progressive azotemia (BUN 32.9 mmol/L [92 mg/dL], crea 875 µmol/L [9.9 mg/dL]), new hyperphosphatemia (2.8 mmol/L [8.6 mg/dL]), and hypocalcemia (iCa 1.9 mmol/L, RI: 2–2.8 mmol/L) (7.5 mg/dL, RI: 7.8–11.3 mg/dL). IV LRS5 was instituted at 128 mL/kg/day. Recheck urinalysis20 while on IV fluids showed a specific gravity of 1.013, 2000+ glucosuria, 300+ proteinuria, and granular debris. At 24 h following ingestion, azotemia was progressive (BUN 41 mmol/L [115 mg/dL], crea 893 µmol/L [10.1 mg/dL]), and the cat was transferred to a tertiary care facility. On presentation, the cat was hypothermic at 36.2°C (97.2°F), <5% dehydrated, painful on kidney palpation, and had mild bilateral photophobia with blepharospasm. Treatment was continued with IV Plasmalyte21 (190 mL/kg/day), maropitant8 (1 mg/kg, IV, q 24 h), and buprenorphine11 (0.01 mg/kg, IV, q 8 h). Overnight, the cat developed scant retroperitoneal, peritoneal, and pleural effusion suspected to be due to fluid overload; therefore, the IV fluid rate was decreased to 45 mL/kg/day. Forty‐eight hours following ingestion, there was persistent azotemia (BUN too high to read, crea 893 µmol/L [10.1 mg/dL]) and hypocalcemia (iCa 0.2 mmol/L, RI: 0.26–0.36 mmol/L) (0.86 mg/dL, RI: 1.04–1.44 mg/dL); additionally, hypertension (systolic blood pressure 182 mm Hg) and hyperphosphatemia (3 mmol/L [9.4 mg/dL]) were noted. Seventy‐two hours after ingestion, the previous concern for fluid overload was supported by a 0.38‐kg weight gain, progressive peritoneal effusion, and peripheral edema. The azotemia was static, with decreased urine output concerning for oliguria. IV fluids were discontinued, and furosemide13 (2 mg/kg, IV, q 6–8 h) was administered. Due to persistent azotemia and fluid overload, referral for hemodialysis was recommended. The owner declined referral and chose to continue inpatient care. Later that day, the cat was anesthetized for placement of an indwelling urinary catheter12 and esophageal feeding tube22. On Day 4 following ingestion, there was less peritoneal and pleural effusion, suggesting the fluid overload had improved. The cat appeared brighter despite progressive azotemia (BUN 88.6 mmol/L [248 mg/dL], crea 1096 µmol/L [12.4 mg/dL], phos too high to read) and persistent hypocalcemia (iCa 0.19 mmol/L [0.76 mg/dL]). Twelve hours after starting intermittent furosemide, the urine output was 3.3 mL/kg/h. Over the next 24 h, the urine output increased to 5.5 mL/kg/h. Furosemide13 was discontinued approximately 48 h after it was started, when the cat became polyuric. Esophageal tube feedings began at 25% RER liquid diet23. On Day 5 after ingestion, the cat's weight decreased to 3.64 kg with 5 mL/kg/h urine output. Azotemia was progressive (BUN too high to read, crea 1317 µmol/L [14.9 mg/dL], phos too high to read) with persistent hypocalcemia (iCa 0.23 mmol/L [0.91 mg/dL]). On Day 6 following ingestion, the cat was tolerating 48 mL/kg/day water and 50% RER via esophageal feeding tube. Azotemia was static (BUN too high to read, crea 1229 µmol/L [13.9 mg/dL]), and the cat was discharged. On Day 9 after ingestion, azotemia had mildly improved (BUN too high to read, crea 937 µmol/L [10.6 mg/dL]). On Day 13, azotemia had significantly improved (BUN 24.3 mmol/L [68 mg/dL], crea 292 µmol/L [3.3 mg/dL]). The CBC4 showed a resolved leukopenia (7.2 × 109/L, RI: 3.6–16 × 109/L) (7.2 × 103/µL, RI: 3.5–16 × 103/µL), resolved neutropenia (5.5 × 109/L, RI: 2.5–8.5 × 109/L) (5.5 × 103/µL, RI: 2.5–8.5 × 103/µL), improved lymphopenia (1.0 × 109/L, RI: 1.2–8.0 × 109/L) (1.0 × 103/µL, RI: 1.2–8.0 × 103/µL), and a hematocrit of 30% (RI: 29%–48%). Urinalysis showed a specific gravity of 1.036, trace glucosuria, 1+ proteinuria, and no casts. On Day 47 after ingestion, recheck serum biochemistry4 showed resolution of azotemia (BUN 8.9 mmol/L [25 mg/dL], crea 88 µmol/L [1 mg/dL], phos 1.3 mmol/L [4 mg/dL]). Discussion AKI was observed with large overdoses of oclacitinib in all three cats in this case series. Additionally, all three cats developed ocular signs, hypocalcemia, abdominal pain, and decreased urine output. Two cats became anuric and died or were euthanized, while the final cat was oliguric and survived after a prolonged treatment course. Both deceased cats had renal tubular necrosis identified on necropsy. All three cats were initially hypokalemic and hypophosphatemic, with two of the three cats becoming hyperkalemic and hyperphosphatemic as their AKI progressed. Two of the three cats had vomiting, elevated ALT, glucosuria, proteinuria, and hypothermia. Additional clinical signs identified bythe American Society for the Prevention of Cruelty to Animals' Animal Poison Control Center (APCC) associated with oclacitinib overdose in both cats and dogs include new onset heart murmur, hypotension, arrhythmias, intraocular pressure changes, ataxia, agitation, ketonuria, and rarely seizures [11]. In APCC's experience, development of GI, CV, and ocular signs occurs within the first 12 h after exposure. Blood work changes in this timeframe may include leukopenia, hepatic enzyme increases, hyperglycemia, and electrolyte disturbances. AKI can develop within 12–36 h and may progress to anuria, death, or humane euthanasia within 24–96 h. The cats in this case series ingested dosages of oclacitinib ranging from 100 to 131 mg/kg. The minimum nephrotoxic dose has not been established; however, APCC has case reports of AKI resulting in death or euthanasia at dosages as low as 6–15 mg/kg in cats [11]. The previously mentioned systemic signs have generally been noted at dosages >10 mg/kg, which is well above the off‐label dosages being used in cats and the dosage evaluated in a cat safety study [2, 11]. Two cats in this series had postmortem analysis that showed acute renal tubular degeneration, necrosis, granular casts, cellular casts, and intratubular mineralization. It is also possible that given the relatively short time frame (<48 h from exposure to euthanasia), the full spectrum of tubular damage may not have manifested morphologically at the time of death. A definitive cause for AKI is not clear based on necropsy findings. Potential mechanisms for toxicant‐induced AKI include ischemia due to acute renal vasoconstriction, decreased renal perfusion, direct nephrotoxicosis resulting in necrosis of renal tubular epithelial cells, or renal tubular obstruction from casts and sloughing epithelial cells [11]. There are reports of cats with severe AKI that made a full recovery within 2–6 weeks of ingestion, even when treated on an outpatient basis [11]. If the toxicant leaves the renal basement membrane intact and renal tubular cells are able to regenerate, the prognosis is not necessarily grave, despite the presence of a severe AKI [11]. The toxic mechanism in oclacitinib toxicosis is unknown. The spectrum of systemic signs may suggest a widespread mechanism present throughout multiple body systems, or a primary AKI with severe uremia and oliguria or anuria. The JAK pathway is intimately involved in systemic proinflammatory and anti‐inflammatory processes, innate and adaptive immune responses, and hematopoiesis. The overall effects of JAK inhibition are dependent on the balance of proinflammatory and anti‐inflammatory cytokines, which are intricately intertwined and not fully defined [14, 15, 16, 17, 18, 19]. This complexity creates a fine line between immune regulation and immune harm, and with overdoses, this interplay is likely further convoluted. Toxicosis could be mediated by imbalance of inflammatory and immunomodulatory effects, inhibition of protective cytokines involved in maintaining normal physiologic function in multiple systems (such as systemic vascular resistance, prostaglandin production, cardiac function, renal protective cytokines, vascular integrity, and rebound phenomenon), or a combination of several mechanisms [20, 21, 22, 23, 24, 25]. Even when JAK inhibitors are targeted at specific receptors, crosstalk may make it difficult to predict the full pathophysiologic effect. This could explain the leukopenia and anemia noted in this case series due to spillover effects on immunomodulation and JAK2 receptors involved with hematopoiesis [26]. Dilutional effects of fluids, inhibition of erythropoietin, and GI ulceration with hemorrhage due to uremia may have also contributed to a progressive anemia in Case 2. Initial hypokalemia and hypophosphatemia could be due to GI losses or intracellular shifting secondary to the intoxicant. Hyperkalemia, hyperphosphatemia, and hypocalcemia were likely secondary to progressive AKI. There have been reports of several cats with AKI and hypocalcemia that have normal or low phosphorus with concurrent glucosuria, proteinuria, and ketonuria [11]; this could indicate urinary loss of calcium secondary to tubular damage. The pleural and peritoneal effusion in Case 3 may have been caused by fluid overload, congestive heart failure, or toxin‐induced vasculitis. As the mechanism of oclacitinib toxicosis is unknown, there is no known antidote. Treatment in these cases was focused on symptomatic and supportive care. The interventions used in these cases included activated charcoal, IV fluids, GI support, pain control, nutritional support, management of oliguria/anuria, and management of fluid overload. The efficacy of activated charcoal is unknown. IV fluid therapy is recommended as indicated by physical examination and blood work. Due to the risk for AKI, decreased urine production, and fluid overload, close monitoring of fluid balance and urine output is essential. For the surviving cat, oliguria and suspected fluid overload was effectively treated with intermittent furosemide. Oclacitinib has low protein binding of 68%, log P of 1.7, molecular size of 338 Da, and volume of distribution of 942 mL/kg. Given these characteristics, advanced decontamination with hemodialysis or hemoperfusion could be effective in the future. Hemodialysis would also be helpful in managing AKI and secondary side effects of severe uremia in cats until renal function is restored. In conclusion, awareness of this emerging toxicosis is vital to ensure prompt treatment and to reduce the risk of exposure. Many cats apparently find this medication very palatable and willingly ingest large quantities. Veterinarians should encourage owners to take extra precautions to secure the medication out of reach. Owners should also consider purchasing the less palatable tablet formulation if there is risk their cat could have access to the medication in the future. Given the novelty of this toxicosis, further research and reporting are necessary to determine the best management protocol for oclacitinib overdose in the future. Author Contributions Jessica Kielb Basile: conceptualization, writing – original draft, writing – review and editing, resources. Sara C. Lister: writing – original draft, conceptualization, writing – review and editing, resources. Ethics Statement The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to. No ethical approval was required as this is a review article with no original research data. Conflicts of Interest The authors declare no conflicts of interest.